Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48weeks in patients with acromegaly
Open Access
- 1 August 2008
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 69 (2), 299-305
- https://doi.org/10.1111/j.1365-2265.2008.03208.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyClinical Endocrinology, 2007
- AcromegalyNew England Journal of Medicine, 2006
- Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialClinical Endocrinology, 2006
- Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor ShrinkageJournal of Clinical Endocrinology & Metabolism, 2006
- Effectiveness and tolerability of 3-year lanreotide AutogelR treatment in patients with acromegalyClinical Endocrinology, 2006
- Consensus statement: medical management of acromegalyActa Endocrinologica, 2005
- One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide AutogelRClinical Endocrinology, 2004
- Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegalyAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Dose and frequency titration of somatostatin analogues in the treatment of acromegaly – an injection of expediency?Clinical Endocrinology, 2001
- Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist PegvisomantNew England Journal of Medicine, 2000